Top 5 Strong Buy Stocks to Invest In

3. McKesson Corporation (NYSE:MCK)

On June 10, 2026, Barclays lowered the firm’s price target on McKesson Corporation (NYSE:MCK) to $925 from $1,050 and maintained an Overweight rating on the shares. Barclays updated estimates and targets in the drug distributor space following recent results. The firm said its new estimates are “incrementally conservative” due to limited visibility around the Inflation Reduction Act, biosimilars, and GLP-1s, though it continues to believe in McKesson’s long-term model.

On June 1, 2026, McKesson Corporation (NYSE:MCK) announced the completion of the previously announced minority ownership investment from funds managed by affiliates of Apollo (APO) in McKesson’s Medical-Surgical Solutions business. Apollo Funds invested $1.25B in convertible preferred equity of MMS to acquire an approximately 13% interest in the business. The transaction values MMS at approximately $13B in total enterprise value, while McKesson retains operating control and majority ownership.

Last month, UBS analyst Kevin Caliendo raised the firm’s price target on McKesson Corporation (NYSE:MCK) to $1,050 from $1,000 and maintained a Buy rating on the shares. Caliendo said that despite the “messy” Q4 print, the initial FY27 outlook looks “good enough.”

McKesson Corporation (NYSE:MCK) provides healthcare services in the United States and internationally.